ORY 2001

Drug Profile

ORY 2001

Alternative Names: ORY-2001

Latest Information Update: 25 Oct 2016

Price : $50

At a glance

  • Originator Oryzon
  • Class Nootropics; Small molecules
  • Mechanism of Action Histone demethylase inhibitors; Lysine specific demethylase 1 inhibitors; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Alzheimer's disease; Dementia; Huntington's disease; Parkinson's disease
  • Preclinical Multiple sclerosis

Most Recent Events

  • 25 Oct 2016 Phase-I clinical trials in Huntington's disease (PO)
  • 12 Sep 2016 Preclinical trials in Multiple sclerosis in Spain (PO)
  • 27 Jul 2016 Adverse events and pharmacodynamics data from a preclinical study in Huntington's disease presented at the Alzheimer's Association International Conference 2016 (AAIC-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top